Brovincamine | CAS# 57475-17-9 | vasodilator

MedKoo Cat#: 412161 | Name: Brovincamine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Brovincamine also known as brovincamine fumarate (BV, Sabromin) was used in Japan mainly as an improver of cerebral circulation and metabolism, and also as an inhibitor of the aggregation of platelets through the cyclic AMP pathway in patients with normal tension glaucoma. Brovincamine exerts its action via calcium channels blockade. Brovincamine is also a vasodilator.

Chemical Structure

Brovincamine

CAS#57475-17-9

Theoretical Analysis

MedKoo Cat#: 412161

Name: Brovincamine

CAS#: 57475-17-9

Chemical Formula: C21H25BrN2O3

Exact Mass: 432.1049

Molecular Weight: 433.35

Elemental Analysis: C, 58.21; H, 5.82; Br, 18.44; N, 6.46; O, 11.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Brovincamine; BV26-723; BV-26-723; BV 26-723

IUPAC/Chemical Name

methyl (41S,12S,13aS)-9-bromo-13a-ethyl-12-hydroxy-2,3,41,5,6,12,13,13a-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate

InChi Key

WYIJGAVIVKPUGJ-GIVPXCGWSA-N

InChi Code

InChI=1S/C21H25BrN2O3/c1-3-20-8-4-9-23-10-7-15-14-6-5-13(22)11-16(14)24(17(15)18(20)23)21(26,12-20)19(25)27-2/h5-6,11,18,26H,3-4,7-10,12H2,1-2H3/t18-,20+,21+/m1/s1

SMILES Code

CC[C@@]12CCCN3CCc(c([C@H]13)n4[C@](C2)(C(OC)=O)O)c5c4cc(Br)cc5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 433.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Araie M, Mayama C. Use of calcium channel blockers for glaucoma. Prog Retin Eye Res. 2011 Jan;30(1):54-71. doi: 10.1016/j.preteyeres.2010.09.002. Epub 2010 Oct 8. PMID: 20933604. 2: Sycha T, Vass C, Findl O, Bauer P, Groke I, Schmetterer L, Eichler HG. WITHDRAWN: Interventions for normal tension glaucoma. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD002222. doi: 10.1002/14651858.CD002222.pub2. PMID: 20166063. 3: Sycha T, Vass C, Findl O, Bauer P, Groke I, Schmetterer L, Eichler H. Interventions for normal tension glaucoma. Cochrane Database Syst Rev. 2003;(4):CD002222. doi: 10.1002/14651858.CD002222. Update in: Cochrane Database Syst Rev. 2010;(2):CD002222. PMID: 14583947. 4: Kitazawa Y. [Open-angle glaucoma clinical presentation and management]. Nippon Ganka Gakkai Zasshi. 2001 Dec;105(12):828-42. Japanese. PMID: 11802456. 5: Koseki N, Araie M, Yamagami J, Shirato S, Yamamoto S. Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. J Glaucoma. 1999 Apr;8(2):117-23. PMID: 10209728. 6: Tawara A, Tanaka T, Tsujioka K, Sudo Y, Ohnishi Y. [Effects of brovincamine fumarate on choroidal blood volume in rabbits]. Nippon Ganka Gakkai Zasshi. 1998 Oct;102(10):654-61. Japanese. PMID: 9834607. 7: Nirei M. [Blood flow changes in the optic nerve head of albino rabbits following intravenous administration of brovincamine fumarate, an improver of cerebral circulation and metabolism]. Nippon Ganka Gakkai Zasshi. 1996 Feb;100(2):118-25. Japanese. PMID: 8851150. 8: Sawada A, Kitazawa Y, Yamamoto T, Okabe I, Ichien K. Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma. Ophthalmology. 1996 Feb;103(2):283-8. doi: 10.1016/s0161-6420(96)30703-3. PMID: 8594515. 9: Takeuchi H, Araki Y, Emaduddin M, Zhang W, Han XY, Salunga TL, Wong SM. Identifiable Achatina giant neurones: their localizations in ganglia, axonal pathways and pharmacological features. Gen Pharmacol. 1996 Jan;27(1):3-32. doi: 10.1016/0306-3623(95)00113-1. PMID: 8742492. 10: Yamada S, Yamaguchi K, Okuyama S. Effects of VA-045 on peripheral and central circulation in anesthetized dogs. Gen Pharmacol. 1995 Oct;26(6):1419-24. doi: 10.1016/0306-3623(94)00306-8. PMID: 7590141. 11: Tanaka Y, Morimoto K, Ishii K, Nakayama K. Calcium antagonistic vasodilator mechanisms of brovincamine fumarate studied in canine cerebral artery. Arzneimittelforschung. 1994 Jul;44(7):803-8. PMID: 7945512. 12: Yamaguchi S, Fukuyama H, Yonekura Y, Konishi J. Effect of brovincamine on cerebral circulation and metabolism in internal carotid artery occlusion examined by positron emission tomography. Eur Neurol. 1992;32(6):314-7. doi: 10.1159/000116851. PMID: 1490496. 13: Morita K, Nakanishi A, Murakumo Y, Oka M, Houchi H. Inhibitory action of brovincamine on catecholamine secretion from cultured bovine adrenal medullary cells: possible relation to its blocking action on Ca2+ channels. Biochem Pharmacol. 1991 Jun 21;42(1):190-2. doi: 10.1016/0006-2952(91)90700-f. PMID: 2069593. 14: Jucker M, Bättig K, Meier-Ruge W. Effects of aging and vincamine derivatives on pericapillary microenvironment: stereological characterization of the cerebral capillary network. Neurobiol Aging. 1990 Jan-Feb;11(1):39-46. doi: 10.1016/0197-4580(90)90060-d. Erratum in: Neurobiol Aging 1990 Nov- Dec;11(6):675. PMID: 2325815. 15: Takeuchi H, Yamamoto N, Sun XP. Comparaison des effets antagonistes de plusieurs drogues sur le courant calcique dans un neurone géant d'un Escargot Africain (Achatina fulica Férussac) [Comparison of antagonistic effects of several drugs on calcium current in a giant neuron of an African snail (Achatina fulica Férussac)]. C R Seances Soc Biol Fil. 1990;184(2):175-80. French. PMID: 2148902. 16: Hasegawa M, Yokoyama K, Kobayashi N, Okamoto A, Tamura T, Watanabe I. Blood pressure and cochlear blood flow in the guinea pig. Acta Otolaryngol. 1989 May- Jun;107(5-6):413-6. doi: 10.3109/00016488909127532. PMID: 2756833. 17: Jucker M, Meier-Ruge W. Effects of brovincamine on stereological capillary parameters in adult and old Fischer-344 rats. Microvasc Res. 1989 May;37(3):298-307. doi: 10.1016/0026-2862(89)90048-4. PMID: 2733602. 18: Matsuda H, Tsuji S, Oba H, Kinuya K, Terada H, Sumiya H, Shiba K, Mori H, Hisada K, Maeda T. Double tracer autoradiographic method for sequential evaluation of regional cerebral perfusion. Am J Physiol Imaging. 1989;4(4):131-5. PMID: 2624815. 19: Suzuki S, Memezawa H, Katayama Y, Shimizu J, Sugimoto S, Nagazumi A, Terashi A. [Effect of brovincamine fumarate on cerebral ischemia acutely induced by BLCL in SHRSR]. No To Shinkei. 1987 Dec;39(12):1117-24. Japanese. PMID: 3446248. 20: Meier-Ruge W, Schulz-Dazzi U. Effects of brovincamine on the stereological parameters of corticocerebral capillaries. Life Sci. 1987 Mar 9;40(10):943-9. doi: 10.1016/0024-3205(87)90313-4. PMID: 3821365.